scispace - formally typeset
C

Caryn Naekyung Kim

Researcher at Emory University

Publications -  12
Citations -  11744

Caryn Naekyung Kim is an academic researcher from Emory University. The author has contributed to research in topics: Apoptosis & Cytochrome c. The author has an hindex of 11, co-authored 12 publications receiving 11468 citations. Previous affiliations of Caryn Naekyung Kim include University of South Florida.

Papers
More filters
Journal ArticleDOI

Induction of apoptotic program in cell-free extracts : requirement for datp and cytochrome c

TL;DR: Cells undergoing apoptosis in vivo showed increased release of cy tochrome c to their cytosol, suggesting that mitochondria may function in apoptosis by releasing cytochrome c.
Journal ArticleDOI

Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked

TL;DR: One possible role of Bcl-2 in prevention of apoptosis is to block cytochrome c release from mitochondria, which is normally located in the mitochondrial intermembrane space.
Journal ArticleDOI

Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling.

TL;DR: In this article, a tetracycline-inducible murine cell lines that express wild-type protein kinase (PKR) or a catalytically inactive PKR variant, PKRdelta6 were developed.
Journal ArticleDOI

Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3

TL;DR: Findings indicate that Bcr-Abl expression blocks apoptosis due to diverse apoptotic stimuli upstream by preventing the cytosolic accumulation of cyt c and other preapoptotic mitochondrial perturbations, thereby inhibiting the activation of caspase-3 and execution of apoptosis.
Journal ArticleDOI

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

TL;DR: In vitro data indicate that combinations of CGP57148B and antileukemic drugs such as Ara-C may have improved in vivo efficacy against Bcr-Abl-positive acute leukemia.